Jasleen Agroia
Family · Folsom, CANPI 1457069296
Payments from drug & device makers
Across 114 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$567
- GSK$443
- Bayer$261
- Exact Sciences$197
- Boehringer Ingelheim$193
- Novo Nordisk$184
- plus $824 from 17 others
What the payments were for
- Food & beverage$2,668100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $567 |
| GSK | 18 | $443 |
| Bayer | 10 | $261 |
| Exact Sciences | 9 | $197 |
| Boehringer Ingelheim | 9 | $193 |
| Novo Nordisk | 9 | $184 |
| Lilly USA, LLC | 7 | $147 |
| Pfizer | 6 | $129 |
| Radius Health, Inc. | 3 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| AbbVie | 2 | $48 |
| Mayne Pharma Commercial LLC | 3 | $47 |
| Vertex | 2 | $41 |
| Almatica Pharma LLC | 1 | $31 |
| Philips North America LLC | 1 | $27 |
| Neuronetics, Inc. | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,668 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $21,837 |
| JardianceEmpagliflozin | 13 | $17,802 |
| EliquisApixaban | 25 | $17,612 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,670 |
| Levothyroxine Sodium | 124 | $1,591 |
| Atorvastatin Calcium | 90 | $1,345 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,328 |
| Temazepam | 15 | $763 |
| Omeprazole | 49 | $757 |
| Famotidine | 45 | $593 |
| Gabapentin | 48 | $588 |
| Alendronate Sodium | 16 | $525 |
| Losartan Potassium | 67 | $520 |
| Zolpidem Tartrate | 53 | $511 |
| Fluticasone Propionate | 31 | $479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $184 | $21,83725 claims |
| Boehringer IngelheimJardiance | $193 | $17,80213 claims |
| PfizerEliquis | $129 | $17,61225 claims |
| Almatica Pharma LLCSertraline Hcl | $31 | $21427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.
Other family in Folsom
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.